A food safety turnaround with supplier bruises
- Neogen is now mainly a Food Safety and Animal Safety company after selling or agreeing to sell non-core units.
- Q3 fiscal 2026 revenue fell to $211.2 million from $221.0 million a year earlier.
- Food Safety grew in Q3, but Animal Safety fell 20.1% because of supplier quality and manufacturing problems.
- Management wants Petrifilm to move beyond food testing into pharmaceuticals, cosmetics, and nutraceuticals.
- The Zoetis deal for Genomics is expected to bring in $160.0 million and help pay down debt if it closes.
Turnaround, with proof still thin
Neogen is a turnaround story. The new team is trying to simplify the company, cut costs, fix operations, and focus on higher-value food safety products. That plan has real pieces behind it: a completed Cleaners and Disinfectants sale, a signed Genomics sale to Zoetis, a $20 million annualized cost reduction plan, and a clearer growth plan for Petrifilm.
The best part of the story is Food Safety. In Q3 fiscal 2026, Food Safety revenue rose to $156.7 million from $152.8 million. Products tied to pathogen detection, indicators, and sample collection helped. Management also says the Petrifilm manufacturing move is still on schedule for November 2026.
The weak part is Animal Safety. Revenue there dropped to $54.5 million from $68.2 million in Q3 fiscal 2026. Management blamed third-party supplier quality and manufacturing issues, and said the impact should continue into the beginning of fiscal 2027. That makes the turnaround less clean.
The bull case needs three things to happen together: close the Genomics sale, bring Petrifilm production in-house without disruption, and show that Animal Safety is stabilizing. The bear case is simple: these problems may not be one-off mistakes. They may show that Neogen still has fragile operations after the 3M Food Safety deal.
Tests, consumables, and channel trust
Neogen makes money by selling testing products, safety products, and related services. Many products are used over and over by food plants, labs, veterinarians, livestock producers, distributors, and animal health customers. That repeat use matters because the company is not only selling machines or one-time projects.
Food Safety is the main engine. Customers use Neogen products to test for pathogens, allergens, toxins, sanitation problems, and other risks in food and feed. Rules around food testing and brand risk can support long-term demand, but food production volumes have been soft.
Animal Safety sells items such as rodent control, insect control, veterinary instruments, disposables, and biosecurity products. It also still includes Genomics until the Zoetis sale closes. This segment is more exposed to cyclical animal markets, supplier problems, and distributor behavior.
The balance sheet is a key part of the story. Neogen had $800.0 million of total debt and finance lease obligations at February 28, 2026, with $159.9 million of cash. Management used proceeds from the Cleaners and Disinfectants sale to repay debt, and plans to use Genomics sale proceeds the same way.
What Neogen sells
Petrifilm and indicator testing
Petrifilm is a core Food Safety platform used for microbial testing. Management now wants to test new uses in pharmaceuticals, cosmetics, nutraceuticals, and other consumer categories.
Pathogen detection
These products help food producers and labs detect harmful organisms. Q3 management commentary said pathogen detection helped drive Food Safety business growth.
Sample collection and culture media
These products support routine testing work in food plants and labs. They are important, but Neogen has had manufacturing inefficiencies after moving some production from 3M into its own facilities.
Natural toxins, allergens, and sanitation tests
These tests help customers check food, feed, and facilities for safety issues. Demand is tied to testing rules, food production, and customer quality programs.
Rodent, insect, and biosecurity products
These Animal Safety products help farms, facilities, and animal owners control pests and disease risks. Recent supplier and tariff-related issues have hurt sales in this area.
Veterinary instruments and disposables
Neogen sells tools and supplies used by vets and animal health customers. The product line has faced pressure from lower demand and supply constraints.
Genomics services
Genomics provides testing services for production and companion animals. Neogen has agreed to sell this business to Zoetis for $160.0 million, so it is more of a near-term deleveraging asset than a long-term core product line.
Food Safety now dominates
Segment mix uses net revenue for the three months ended February 28, 2026. Food Safety was about three quarters of revenue, but Genomics remains inside reported segments until the Zoetis deal closes.
What could break the plan
Animal Safety supplier failure
High impact · High oddsAnimal Safety revenue fell 20.1% in Q3 fiscal 2026. Management blamed third-party supplier quality and manufacturing issues and said the drag should continue into early fiscal 2027. A new supplier qualification program may help, but it has not yet proved it can restore revenue.
Petrifilm transfer disruption
High impact · Medium oddsNeogen is bringing Petrifilm manufacturing in-house, with management saying the November 2026 transition is on schedule. This is central to the Food Safety moat and margin story. If the transfer causes quality issues, backlogs, or lost customers, the bull case weakens fast.
Controls and reporting weakness
High impact · Medium oddsNeogen has disclosed material weaknesses in internal control over financial reporting. That means its systems and processes did not give enough assurance that financial reporting was reliable. The issue matters more during a complex turnaround with divestitures, restructuring, and integration work.
Debt limits the margin for error
Medium impact · Medium oddsAt February 28, 2026, Neogen had $800.0 million of total debt and finance lease obligations. The company was in compliance with its credit covenants, and the Genomics sale could help reduce debt. Still, higher interest costs and weak earnings leave less room for mistakes.
Food Safety demand stays soft
Medium impact · Medium oddsFood Safety is the better business, but its end market has been hurt by lower food production. Management expects growth rates to improve, yet that depends on customers producing more and keeping testing budgets healthy. Distributor inventory swings can also make Petrifilm demand look choppy.
3M integration and litigation overhang
Medium impact · Medium oddsThe 3M Food Safety acquisition is still a source of operational risk. Prior integration challenges contributed to a large goodwill impairment in fiscal 2025, and the Q3 filing also described shareholder litigation tied to the integration. Even if the claims are defended, they add cost and distraction.
In one breath
What does Neogen Corporation do?
Neogen sells food and animal safety products. Its Food Safety products help test food, feed, and facilities for contamination, while Animal Safety products serve vets, farms, livestock producers, and animal health channels.
Why is Neogen selling Genomics?
Management wants to simplify the company and focus on core Food Safety and Animal Safety products. Neogen agreed to sell Genomics to Zoetis for $160.0 million and expects to use proceeds to reduce debt.
What is Petrifilm, and why does it matter?
Petrifilm is a key Food Safety testing platform that came with the 3M Food Safety business. Neogen wants to bring its manufacturing in-house and expand its use beyond food testing into areas like pharmaceuticals and cosmetics.
What is the biggest near-term risk for Neogen stock?
The clearest near-term risk is execution. Investors need to see Animal Safety stabilize, the Genomics sale close, and the Petrifilm manufacturing move stay on schedule without hurting customers.